Our findings suggest that MCP‐1‐associated neuroinflammation may play a crucial role in the pathogenesis of TS, indicating that targeting MCP‐1 could be a promising therapeutic approach for managing TS symptoms. This evidence concerns the gene CCL2 and Timothy syndrome.